Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 9/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | LCAT | P04180 | 2/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | CCNC | P24863 | 1/20 | 0.40 |
| ▸ | CDK8 | P49336 | 1/20 | 0.40 |
| ▸ | RBP4 | P02753 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20734741 | 0.84 | DHFR (0.50) | DHFRLCAT | |
| SCHEMBL20804283 | 0.80 | DHFR (1.00) | DHFR | |
| SCHEMBL10690764 | 0.79 | DHFR (0.63) | DHFR | |
| SCHEMBL4492813 | 0.76 | DHFR (0.56) | DHFRCYP3A4LCATHRH3CCNC | |
| SCHEMBL10690355 | 0.76 | MEN1 (0.54) | DHFRHRH3 | |
| SCHEMBL28323089 | 0.76 | MEN1 (0.48) | DHFR | |
| SCHEMBL10691450 | 0.76 | DHFR (0.65) | DHFRHRH3 | |
| SCHEMBL10686944 | 0.76 | DHFR (0.45) | DHFR | |
| SCHEMBL16648419 | 0.75 | DHFR (0.50) | DHFRCYP3A4LCATHRH3CCNC | |
| SCHEMBL31615430 | 0.74 | CYP3A4 (0.55) | DHFRCYP3A4LCATHRH3CCNC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200270233-A1 | DHFR INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO | Vyera Pharmaceuticals, LLC | 2020-08-27 | — | — | US | disclosed |
| WO-2019032458-A1 | DHFR INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO | Vyera Pharmaceuticals, LLC (US) | 2019-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200270233-A1 | DHFR INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO | DHFR, DHODH, FPGS | DHFR 1/4885CYP3A4 1013/4885LCAT 390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.